The Times Australia
The Times Australia
.

Trump has flagged 200% tariffs on Australian pharmaceuticals. What do we produce here, and what’s at risk?

  • Written by Joe Carrello, Research Fellow, The University of Melbourne

US President Donald Trump’s proposed tariffs on Australia’s pharmaceutical exports to the United States has raised alarm among industry and government leaders.

There are fears that, if implemented, the tariffs could cost the Australian economy[1] up to A$2.8 billion. That’s both in direct exports and as inputs to third countries that produce drugs also hit by tariffs.

The proposed tariffs come amid growing pressure from pharmaceutical lobby groups in the US for Trump to use trade negotiations as a tool to make changes to the Pharmaceutical Benefits Scheme (PBS) and raise Australian drug prices.

In response, Treasurer Jim Chalmers stated the government would not compromise[2] the integrity of the PBS to do a deal with the Trump administration. Nationals Senator Bridget McKenzie also confirmed bipartisan support[3] for the PBS.

Our largest export market for pharmaceuticals

The US is Australia’s biggest pharmaceutical export market, accounting for 38% of total Australian pharmaceutical exports and valued at $2.2 billion[4] last year.

About 87% of exports to the US[5] consist of blood plasma products, mainly from manufacturing giant CSL[6]. These are used for transfusions in a range of medical[7] and surgical situations.

In a submission to the US Commerce Department, which is reviewing the sector, CSL called for tariffs to be phased in[8] over five years, and for an exemption for certain biotech equipment.

Trump floated proposed tariffs potentially as high as 200%. But he also said these would not be imposed for “about a year[9], a year and a half” to allow negotiations to take place.

If tariffs are eventually implemented, there are fears domestic manufacturing may suffer[10], with negative flow-on effects for Australian research and innovation[11] in the sector.

Biotechnology company CSL’s office is seen in Parkville, Melbourne
Pharmaceutical giant CSL makes blood plasma products. Erik Anderson/AAP

How does the PBS work?

The PBS is an Australian government program aimed at providing affordable prescription medicines[12] to Australians.

It helps reduce the cost of essential medications, ensuring access to treatments for a wide range[13] of medical conditions. Medicines included on the PBS are subsidised by the government, with the patient making a capped co-payment. More than 900 medicines[14] were listed on the scheme in 2023–24, costing the government $17.7 billion.

Decisions to list medications on the PBS are made by the health minister based on recommendations from the Pharmaceutical Benefits Advisory Committee. The committee evaluates the clinical effectiveness, safety, cost-effectiveness (“value for money”) and estimated financial impact of new medications.

If approved, the PBS uses this information to negotiate directly with pharmaceutical companies, helping to keep prices affordable.

How does the US system compare?

This contrasts with the US system, which operates more under free-market principles. In the US, pharmaceuticals are subsidised through private health insurance or government programs such as Medicaid. Neither directly negotiates with pharmaceutical companies.

The fragmented nature of the US system enables pharmaceutical companies to maintain higher prices, as there is no central authority to enforce cost controls. Studies have shown that prices for pharmaceuticals in the US[15] are, on average, 2.78 times those in 33 other countries.

In addition, in the US pharmaceutical companies are granted extensive patent protections. These provide exclusive rights to sell their drugs for a certain period.

This exclusivity often leads to monopolistic pricing[16] practices, as generic competitors are barred from entering the market until the patent expires.

In Australia, patents also exist. But the PBS mitigates their impact by negotiating prices and promoting the use of cost-effective alternatives, such as generics, once they become available.

Industry lobbying

US pharmaceutical industry bodies have long criticised[17] the PBS. They claim[18] the scheme “undervalues new innovative medicines by setting prices based on older inferior medicines and generics, and through use of low and outdated monetary thresholds per year of life gained from clinically proven treatments”.

The slow process to list drugs on the PBS has also attracted criticism[19]. The advisory committee meets only three times a year, with resources currently being stretched beyond capacity.

In response to these criticisms, the Australian government commissioned a review[20], which was completed in 2024. It provided 50 recommendations to ensure Australians can continue to access effective, safe and affordable medicines in an equitable and timely way.

The government has established an advisory group to work on implementing these recommendations. However, it is unclear whether proposed changes will appease the powerful US pharmaceutical industry.

References

  1. ^ cost the Australian economy (www.theaustralian.com.au)
  2. ^ would not compromise (www.abc.net.au)
  3. ^ bipartisan support (www.theguardian.com)
  4. ^ valued at $2.2 billion (www.abc.net.au)
  5. ^ 87% of exports to the US (www.abs.gov.au)
  6. ^ CSL (www.afr.com)
  7. ^ range of medical (www.lifeblood.com.au)
  8. ^ phased in (www.afr.com)
  9. ^ about a year (www.abc.net.au)
  10. ^ manufacturing may suffer (7news.com.au)
  11. ^ research and innovation (www.theaustralian.com.au)
  12. ^ affordable prescription medicines (theconversation.com)
  13. ^ wide range (www.servicesaustralia.gov.au)
  14. ^ 900 medicines (theconversation.com)
  15. ^ in the US (www.rand.org)
  16. ^ monopolistic pricing (time.com)
  17. ^ long criticised (cdn.aglty.io)
  18. ^ claim (www.theaustralian.com.au)
  19. ^ also attracted criticism (theconversation.com)
  20. ^ review (www.health.gov.au)

Read more https://theconversation.com/trump-has-flagged-200-tariffs-on-australian-pharmaceuticals-what-do-we-produce-here-and-whats-at-risk-260909

Graphic warnings on tobacco products are losing their impact – here are 5 ways to improve them

Large pictorial warning labels on smoked tobacco products typically feature confronting images of the harmfu...

Times Magazine

Building a Strong Online Presence with Katoomba Web Design

Katoomba web design is more than just creating a website that looks good—it’s about building an online presence that reflects your brand, engages your audience, and drives results. For local businesses in the Blue Mountains, a well-designed website a...

September Sunset Polo

International Polo Tour To Bridge Historic Sport, Life-Changing Philanthropy, and Breath-Taking Beauty On Saturday, September 6th, history will be made as the International Polo Tour (IPT), a sports leader headquartered here in South Florida...

5 Ways Microsoft Fabric Simplifies Your Data Analytics Workflow

In today's data-driven world, businesses are constantly seeking ways to streamline their data analytics processes. The sheer volume and complexity of data can be overwhelming, often leading to bottlenecks and inefficiencies. Enter the innovative da...

7 Questions to Ask Before You Sign IT Support Companies in Sydney

Choosing an IT partner can feel like buying an insurance policy you hope you never need. The right choice keeps your team productive, your data safe, and your budget predictable. The wrong choice shows up as slow tickets, surprise bills, and risky sh...

Choosing the Right Legal Aid Lawyer in Sutherland Shire: Key Considerations

Legal aid services play an essential role in ensuring access to justice for all. For people in the Sutherland Shire who may not have the financial means to pay for private legal assistance, legal aid ensures that everyone has access to representa...

Watercolor vs. Oil vs. Digital: Which Medium Fits Your Pet's Personality?

When it comes to immortalizing your pet’s unique personality in art, choosing the right medium is essential. Each artistic medium, whether watercolor, oil, or digital, has distinct qualities that can bring out the spirit of your furry friend in dif...

The Times Features

How much money do you need to be happy? Here’s what the research says

Over the next decade, Elon Musk could become the world’s first trillionaire[1]. The Tesla board recently proposed a US$1 trillion (A$1.5 trillion) compensation plan, if Musk ca...

NSW has a new fashion sector strategy – but a sustainable industry needs a federally legislated response

The New South Wales government recently announced the launch of the NSW Fashion Sector Strategy, 2025–28[1]. The strategy, developed in partnership with the Australian Fashion ...

From Garden to Gift: Why Roses Make the Perfect Present

Think back to the last time you gave or received flowers. Chances are, roses were part of the bunch, or maybe they were the whole bunch.   Roses tend to leave an impression. Even ...

Do I have insomnia? 5 reasons why you might not

Even a single night of sleep trouble can feel distressing and lonely. You toss and turn, stare at the ceiling, and wonder how you’ll cope tomorrow. No wonder many people star...

Wedding Photography Trends You Need to Know (Before You Regret Your Album)

Your wedding album should be a timeless keepsake, not something you cringe at years later. Trends may come and go, but choosing the right wedding photography approach ensures your ...

Can you say no to your doctor using an AI scribe?

Doctors’ offices were once private. But increasingly, artificial intelligence (AI) scribes (also known as digital scribes) are listening in. These tools can record and trans...